Friday, 19 Oct 2018

You are here

Maternal RA Increases Offspring Risk of Autoimmune Disorders

A Danish population study suggests that fetal exposure to maternal rheumatoid arthritis (RA) results in an increased offspring risk of thyroid disease, epilepsy and RA, compared to children born to mothers without RA.

Researchers examined a possible association between maternal RA and 15 select chronic diseases in the offspring in a national cohort study using Danish health registries. They examined 2106 children born to RA women (exposed) between 1989 and 2013 and compared outcomes to 1,378,539 children born by women without RA (unexposed).

Exposure to maternal RA resulted in an increased offspring risk for:

  • Thyroid diseases (hazard ratio [HR] 2.19; 95% confidence interval [95% CI] 1.14–4.21)
  • Epilepsy (HR 1.61; 95% CI 1.16–2.25)
  • RA 2.89 (HR 95% CI 2.06–4.05).

Increased but not significant were the odds of developing anxiety, personality disorders and chronic lung disease, including asthma (HR range of 1.15–1.16).

This registry, population-based analysis suggests in utero exposure to maternal RA is associated with an increased risk of select autoimmune conditions, including RA.  While there was a nearly 2-3 fold risk of these autoimmune conditions the overall individual risk still remained quite low (RA exposed risk to offspring was 1.6% compared with 0.7% in unexposed).

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Predictive Risk Factors for Uveitis in JIA

Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.

Elder Rheumatoids Less Likely to Receive Biologics

Multiple studies have shown that elderly rheumatoid arthritis (RA) patients tend to be under-treated and receive DMARD therapies less often than younger RA patients. Now a VAMC study shows that the elderly are less likely to receive biologic agents yet are as likely to be subjected to glucocorticoid use.

Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use.

Defining Refractory Rheumatoid Arthritis

Researchers from the British Society for Rheumatology Biologics (BSRBR) set out to define under what circumstances will rheumatoid arthritis (RA) patients manifest biologic disease-modifying antirheumatic drugs (bDMARDs) refractory disease.

Using the patients from the BSRBR Register (2001 to 2014) they defined patients as bDMARD refractory when they initiated their third class of bDMARD.

Venous Thromboembolism Increased with Rheumatoid Arthritis, Not with TNF Inhibition

Venous thromboembolism (VTE) is a common adverse event throughout medicine and includes both pulmonary embolism (PE) and deep vein thrombosis (DVT).   The cost of diagnosing a thromboembolic event is approximately $4000 - $5550, while the annual cost of treating one case of VTE is between $17,000 and $19,000. The impact of VTE is substantial.